<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open Diabetes Res Care</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open Diabetes Res Care</journal-id><journal-id journal-id-type="hwp">bmjdrc</journal-id><journal-id journal-id-type="publisher-id">bmjdrc</journal-id><journal-title-group><journal-title>BMJ Open Diabetes Research &#x00026; Care</journal-title></journal-title-group><issn pub-type="epub">2052-4897</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26464804</article-id><article-id pub-id-type="pmc">4597415</article-id><article-id pub-id-type="publisher-id">bmjdrc-2015-000131</article-id><article-id pub-id-type="doi">10.1136/bmjdrc-2015-000131</article-id><article-categories><subj-group subj-group-type="heading"><subject>Epidemiology/Health Services Research</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1867</subject></subj-group></article-categories><title-group><article-title>Challenges of diabetes prevention in the real world: results and lessons from the Melbourne Diabetes Prevention Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dunbar</surname><given-names>James A</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hernan</surname><given-names>Andrea L</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Janus</surname><given-names>Edward D</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vartiainen</surname><given-names>Erkki</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Laatikainen</surname><given-names>Tiina</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af4">4</xref><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Versace</surname><given-names>Vincent L</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>John</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Best</surname><given-names>James D</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Skinner</surname><given-names>Timothy C</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>O'Reilly</surname><given-names>Sharleen L</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Mc Namara</surname><given-names>Kevin P</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bennett</surname><given-names>Catherine M</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carter</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib><on-behalf-of>on behalf of the Melbourne Diabetes Prevention Study (MDPS) research group</on-behalf-of></contrib-group><aff id="af1"><label>1</label><addr-line>Faculty of Health</addr-line>, <institution>Deakin Population Health Strategic Research Centre, Deakin University, Melbourne Burwood Campus</institution>, <addr-line>Burwood, Victoria</addr-line>, <country>Australia</country></aff><aff id="af2"><label>2</label><addr-line>Greater Green Triangle University Department of Rural Health</addr-line>, <institution>Flinders and Deakin Universities</institution>, <addr-line>Warrnambool, Victoria</addr-line>, <country>Australia</country></aff><aff id="af3"><label>3</label><institution>Western Academic Centre, Western Centre for Health Research and Education, Western Health, University of Melbourne</institution>, <addr-line>St. Albans, Victoria</addr-line>, <country>Australia</country></aff><aff id="af4"><label>4</label><institution>National Institute for Health and Welfare</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff><aff id="af5"><label>5</label><addr-line>Faculty of Health Sciences</addr-line>, <institution>Institute of Public Health and Clinical Nutrition, University of Eastern Finland</institution>, <addr-line>Kuopio</addr-line>, <country>Finland</country></aff><aff id="af6"><label>6</label><addr-line>Faculty of Medicine, Nursing and Health Sciences</addr-line>, <institution>Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country>Australia</country></aff><aff id="af7"><label>7</label><institution>Lee Kong Chian School of Medicine, Nanyang Technological University and Imperial College London</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="af8"><label>8</label><institution>School of Psychological and Clinical Sciences, Charles Darwin University</institution>, <addr-line>Darwin, Northern Territory</addr-line>, <country>Australia</country></aff><aff id="af9"><label>9</label><institution>Centre for Physical Activity and Nutrition Research, Deakin University, Melbourne Burwood Campus</institution>, <addr-line>Burwood, Victoria</addr-line>, <country>Australia</country></aff><aff id="af10"><label>10</label><addr-line>Faculty of Pharmacy and Pharmaceutical Sciences</addr-line>, <institution>Centre for Medicine Use and Safety, Monash University</institution>, <addr-line>Parkville, Victoria</addr-line>, <country>Australia</country></aff><aff id="af11"><label>11</label><addr-line>Faculty of Health, Deakin Health Economics</addr-line>, <institution>Deakin University, Melbourne Burwood Campus</institution>, <addr-line>Burwood, Victoria</addr-line>, <country>Australia</country></aff><author-notes><corresp><label>Correspondence to</label> Dr James A Dunbar; <email>james.dunbar@deakin.edu.au</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><volume>3</volume><issue>1</issue><elocation-id>e000131</elocation-id><history><date date-type="received"><day>13</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>1</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjdrc-2015-000131.pdf"/><abstract><sec><title>Objective</title><p>To assess effectiveness and implementability of the public health programme <italic>Life! Taking action on diabetes</italic> in Australian people at risk of developing type 2 diabetes.</p></sec><sec><title>Research design and methods</title><p>Melbourne Diabetes Prevention Study (MDPS) was a unique study assessing effectiveness of <italic>Life!</italic> that used a randomized controlled trial design. Intervention participants with AUSDRISK score &#x02265;15 received 1 individual and 5 structured 90&#x02005;min group sessions. Controls received usual care. Outcome measures were obtained for all participants at baseline and 12&#x02005;months and, additionally, for intervention participants at 3&#x02005;months. Per protocol set (PPS) and intention to treat (ITT) analyses were performed.</p></sec><sec><title>Results</title><p>PPS analyses were considered more informative from our study. In PPS analyses, intervention participants significantly improved in weight (&#x02212;1.13&#x02005;kg, p=0.016), waist circumference (&#x02212;1.35&#x02005;cm, p=0.044), systolic (&#x02212;5.2&#x02005;mm&#x02005;Hg, p=0.028) and diastolic blood pressure (&#x02212;3.2&#x02005;mm&#x02005;Hg, p=0.030) compared with controls. Based on observed weight change, estimated risk of developing diabetes reduced by 9.6% in the intervention and increased by 3.3% in control participants. Absolute 5-year cardiovascular disease (CVD) risk reduced significantly for intervention participants by 0.97 percentage points from 9.35% (10.4% relative risk reduction). In control participants, the risk increased by 0.11 percentage points (1.3% relative risk increase). The net effect for the change in CVD risk was &#x02212;1.08 percentage points of absolute risk (p=0.013).</p></sec><sec><title>Conclusions</title><p>MDPS effectively reduced the risk of diabetes and CVD, but the intervention effect on weight and waist reduction was modest due to the challenges in recruiting high-risk individuals and the abbreviated intervention.</p></sec></abstract><kwd-group><kwd>Type 2 Diabetes</kwd><kwd>Cardiovascular Prevention</kwd><kwd>Intervention</kwd><kwd>Public Health</kwd></kwd-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><caption><title>Key messages</title></caption><list list-type="bullet"><list-item><p>Questionnaires are an inexpensive and rapid way to screen for people at risk of diabetes and to raise awareness of an individual's risk.</p></list-item><list-item><p>The threshold criterion used for an Australian questionnaire, AUSDRISK, resulted in recruitment of participants at very low risk of progression to diabetes or cardiovascular disease.</p></list-item><list-item><p>For entry to diabetes prevention programmes, the use of questionnaires should be combined with measurement of impaired fasting glucose, impaired glucose tolerance, or glycosylated hemoglobin.</p></list-item></list></boxed-text><boxed-text position="float" orientation="portrait"><caption><title>Research questions</title></caption><list list-type="bullet"><list-item><p>Knowledge about cost-effectiveness of interventions to prevent progression to diabetes is limited. What should be the questionnaire cut-off points for screening by clinical tests for entry to interventions that would give best value for money?</p></list-item><list-item><p>How can implementation in the real world be improved to maintain the effects of interventions observed under trial conditions?</p></list-item><list-item><p>How could quality improvement techniques be used to improve the effectiveness of diabetes prevention interventions in the real world?</p></list-item></list></boxed-text><p>Recent assessments indicate that 8.3% of adults worldwide (382 million people) have diabetes, and total numbers are projected to exceed 592 million within 25&#x02005;years.<xref rid="R1" ref-type="bibr">1</xref> Effective prevention is critical to reduce this looming burden of disease. In the randomized controlled setting, efficacy has been shown for lifestyle interventions, with progression to type 2 diabetes mellitus (T2DM) reduced by up to 58%,<xref rid="R2" ref-type="bibr">2&#x02013;4</xref> and with beneficial effects evident at 13&#x02005;years follow-up.<xref rid="R5" ref-type="bibr">5</xref> Guidelines have been produced and a systematic review has identified 22 small-scale, real-world translational diabetes prevention programmes.<xref rid="R6" ref-type="bibr">6&#x02013;8</xref> Little is known about their cost-effectiveness or their impact on cardiovascular disease (CVD), the main cause of morbidity and mortality in diabetes.<xref rid="R6" ref-type="bibr">6</xref> Only two scaled-up programmes have been reported to date: FIN D2D<xref rid="R9" ref-type="bibr">9</xref> and <italic>Life! Taking action on diabetes (Life!).</italic><xref rid="R10" ref-type="bibr">10</xref></p><p><italic>Life!</italic> is a statewide, group-based, lifestyle modification programme, targeting people at high risk of developing T2DM in Victoria, Australia.<xref rid="R10" ref-type="bibr">10</xref> Funded by the Victorian Government Department of Health and coordinated by Diabetes Australia&#x02014;Victoria, it was modified in 2012 to <italic>Life! Helping you prevent diabetes, heart disease and stroke</italic>, with revised inclusion criteria and further programme development to specifically include CVD prevention (see online supplementary file 1). Approximately 25&#x02005;000 people have participated in the <italic>Life!</italic> programme since 2007. The five programme goals, targeting improved diet and physical activity, are from the Finnish Diabetes Prevention Study (FIN DPS).<xref rid="R4" ref-type="bibr">4</xref> The system design is drawn from the <italic>Good Ageing in Lahti</italic> (GOAL) implementation trial,<xref rid="R11" ref-type="bibr">11</xref> and is a scaled-up version of the Greater Green Triangle Diabetes Prevention Project (GGT DPP), an Australian Government-funded national demonstrator project.<xref rid="R12" ref-type="bibr">12</xref> During 2009&#x02013;2014 the Melbourne Diabetes Prevention Study (MDPS) evaluated the effectiveness of the <italic>Life</italic>! programme. The objective was to learn from its results in order to further improve the programme and to describe the challenges of real-world diabetes prevention. Using a randomized controlled trial (RCT) for evaluation of a scaled-up, real-world diabetes prevention programme is unique.</p><p>Efficacy studies emphasize <italic>internal validity</italic> and ask &#x02018;Can it work?&#x02019;, excluding real-world factors, so the intervention alone is measured. Effectiveness studies ask &#x02018;Does it work?&#x02019; in the real world, thus providing some indication of <italic>external validity</italic> and generalizability.<xref rid="R13" ref-type="bibr">13&#x02013;15</xref> Scaling-up refers to widespread adoption of interventions among real-world populations that retain or improve their effectiveness, affordability, and sustainability. Because of external, real-world factors, policies based on apparently sound evidence from RCTs may lead to implementation strategies that can encounter practical problems when scaled-up within complex health systems.<xref rid="R16" ref-type="bibr">16</xref></p><p>The challenge now is to translate the positive outcomes from efficacy trials into effective real-world diabetes prevention programmes. Since there is little experience in how to translate such programmes, we also drew on emerging methodologies, like the Dynamic Sustainability Framework (DSF), which provided a guide for implementation.<xref rid="R17" ref-type="bibr">17</xref> We apply the concepts of programme drift and voltage drop from the DSF when reporting the results of the MDPS to categorize the lessons from scaling-up to a statewide programme for which sustainability is also relevant. Our aim is that other countries can learn from our experience when they implement their own large-scale programmes.</p><sec id="s1"><title>Research design and methods</title><p>The trial protocol, outlined briefly below, has been published elsewhere.<xref rid="R18" ref-type="bibr">18</xref></p><sec id="s1a"><title>Study design</title><p>MDPS was a unique prospective parallel group RCT to assess the effectiveness of the <italic>Life!</italic> programme implemented in Victoria, Australia, for people 50&#x02013;75&#x02005;years old at risk of developing T2DM (note the <italic>Life!</italic> inclusion criteria, including age, evolved over the period of the RCT). Over 8&#x02005;months, intervention participants received a diabetes prevention programme and controls received usual care from their general practitioners (GPs). Online supplementary file 2 shows the CONSORT diagram.</p></sec><sec id="s1b"><title>Recruitment</title><p>Eastern Melbourne metropolitan participants were recruited from general practices, accredited <italic>Life!</italic> provider organizations, pharmacies, community organizations, and events. To maximize recruitment and retention, multiple modes of participant contact were collected and used to engage participants. Developing a social connection with participants was important. The same nurse was responsible for all participant contacts and testing during the study.</p></sec><sec id="s1c"><title>Eligibility</title><p>Individuals scoring &#x02265;15 on AUSDRISK aged 50&#x02013;75&#x02005;years were eligible.<xref rid="R19" ref-type="bibr">19</xref> A score of 15&#x02013;19 represents a one-in-seven risk of developing diabetes in 5&#x02005;years, and scores of &#x02265;20 a one-in-three risk. Exclusion criteria were: existing diabetes, laboratory evidence of existing T2DM defined as having a 2&#x02005;h oral glucose tolerance test (OGTT) result of &#x02265;11.1&#x02005;mmol/L and/or a fasting plasma glucose (FPG) &#x02265;7&#x02005;mmol/L, severe mental illness, substance abuse, myocardial infarction within previous 3&#x02005;months, pregnancy, difficulty with English, and other household members already involved in the study.</p></sec><sec id="s1d"><title>Randomization</title><p>Randomization occurred after eligibility was confirmed at baseline testing, described below. Individuals who were found to already have T2DM at baseline were excluded (FPG &#x02265;7&#x02005;mmol/L and/or 2&#x02005;h glucose &#x02265;11.1&#x02005;mmol/L on OGTT). Randomization occurred using a sealed-envelope system, containing randomizations sourced from a random number table allocating participants to study arms in a 1:1 ratio.</p></sec><sec id="s1e"><title>Intervention</title><p>The intervention consisted of an initial 30&#x02013;45&#x02005;min individual session followed by five structured 90&#x02005;min group sessions. The goals were: &#x02264;30% energy from fat; &#x02264;10% energy from saturated fat; &#x02265;15&#x02005;g/1000&#x02005;kcal fiber; &#x02265;30&#x02005;min/day moderate-intensity physical activity; and &#x02265;5% body weight reduction.<xref rid="R4" ref-type="bibr">4</xref> Lifestyle change processes and detailed goals were individually tailored using problem-solving and goal-setting approaches. Trained MDPS facilitators (backgrounds in psychology, nutrition/dietetics and nursing) delivered all intervention sessions. The individual session was designed to maximize participant retention, increase personal risk awareness, undertake goal setting, and motivate change. Four group sessions followed at two-week intervals (generally 8&#x02013;15 participants per group) and the final fifth session occurred 8&#x02005;months after the initial group session (<xref ref-type="fig" rid="BMJDRC2015000131F1">figure 1</xref>). Control participants were told of their high risk but continued with usual care from their GPs.</p><fig id="BMJDRC2015000131F1" orientation="portrait" position="float"><label>Figure&#x000a0;1</label><caption><p>Structure of the Melbourne Diabetes Prevention Study (MDPS).</p></caption><graphic xlink:href="bmjdrc2015000131f01"/></fig><p>The intervention followed the Health Action Process Approach framework.<xref rid="R20" ref-type="bibr">20&#x02013;22</xref> Facilitators moderated discussions on problem solving and goal setting, provided feedback, and strengthened the groups&#x02019; social support role. Feedback on participant outcome measures was provided after testing at 3&#x02005;months (see below) and was used to highlight intervention impact and sustain participants&#x02019; motivation for lifestyle change.</p></sec><sec id="s1f"><title>Anthropometric measurements and laboratory testing</title><p>Anthropometric measurements followed international recommendations: WHO's Multinational MONItoring of Trends and Determinants in CArdiovascular Disease (MONICA) protocol and current European Health Risk Monitoring project.<xref rid="R23" ref-type="bibr">23</xref>
<xref rid="R24" ref-type="bibr">24</xref> Both groups underwent anthropometric and laboratory tests at baseline (T1) and 12&#x02005;months (T3; weight, waist circumference, blood pressure (BP), fasting triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, FPG, 2&#x02005;h OGTT glucose, glycated hemoglobin). Intervention participants additionally underwent these tests, except OGTT, at 3&#x02005;months (T2; <xref ref-type="fig" rid="BMJDRC2015000131F1">figure 1</xref>). All anthropometric measurements were performed by trained nurses using the same equipment at all time points. Laboratory analyses were performed by Melbourne Pathology (NATA accredited with CDC traceable standardization). Participants self-reported dietary intake at T1 and T3 (Food Frequency Questionnaire, FFQ),<xref rid="R25" ref-type="bibr">25</xref> and physical activity at T1, T2 and T3 (Active Australia questionnaire).<xref rid="R26" ref-type="bibr">26</xref></p></sec><sec id="s1g"><title>Outcome assessments</title><p>Primary outcomes were estimated changes in risk of progression to diabetes and CVD determined from changes in weight, waist circumference, FPG, 2&#x02005;h glucose on the OGTT, BP, and lipids. Predicted reduction in diabetes risk was estimated from the effects of weight reduction in the lifestyle arm of the US Diabetes Prevention Program, where risk reduced by 10% for each percentage point of weight loss at 6&#x02005;months.<xref rid="R27" ref-type="bibr">27</xref> There is evidence that the relationship is linear<xref rid="R9" ref-type="bibr">9</xref>
<xref rid="R28" ref-type="bibr">28</xref>
<xref rid="R29" ref-type="bibr">29</xref> and that even modest weight reduction can reduce the risk of developing diabetes.<xref rid="R30" ref-type="bibr">30</xref> An ongoing association between initial weight loss and reduced diabetes risk is supported by several clinical trials.<xref rid="R27" ref-type="bibr">27</xref>
<xref rid="R31" ref-type="bibr">31</xref>
<xref rid="R32" ref-type="bibr">32</xref></p><p>CVD risk was calculated for participants without pre-existing CVD at recruitment using a modified Framingham risk equation including age, total serum cholesterol, HDL-cholesterol, sex, systolic BP, smoking status, and diabetes status (all participants non-diabetic at baseline).<xref rid="R33" ref-type="bibr">33</xref></p></sec><sec id="s1h"><title>Sample size and power calculation</title><p>The power calculation was based on our previous study,<xref rid="R12" ref-type="bibr">12</xref> and provided sufficient power to assess the effect on weight, waist circumference, FPG, HDL-cholesterol, and diastolic BP. The RCT was designed to detect a 0.23 effect size on diastolic BP with 80% power and 5% significance level. Diastolic BP as an outcome measure was predicted to need the largest sample size, requiring 398 participants in each arm, allowing for 25% attrition.<xref rid="R18" ref-type="bibr">18</xref> Owing to slow accrual of participants, combined with MDPS fixed-term funding, 342 were ultimately randomized into the study&#x02014;177 intervention and 165 control. The revised effect size for diastolic BP that could be detected with a two-sided, two-sample t test at the 5% significance level and 80% power was 0.30.</p></sec><sec id="s1i"><title>Data analysis</title><p>Analyses of primary end points were performed using SPSS V.20 and independently verified in GenStat Release V.16.1. Participants&#x02019; baseline characteristics are presented as summary measures. Analyses were carried out for all participants randomized to the study (intention to treat (ITT) set) and for the per protocol set (PPS), sometimes referred to as the modified ITT analysis set; the subset of participants in the full analysis set without major protocol deviations. Such protocol deviations were determined independently of and prior to the unblinding of the trial statistician. These included postbaseline assessments beyond the specified time window (n=2); randomized to control group but attended a <italic>Life!</italic> group or randomized to intervention and household member attended a <italic>Life!</italic> group (n=2); medical conditions potentially causing large weight loss or gain (colon resection, recent mastectomy, removal of skin flaps) (n=3); sharing residence with someone randomized to a different arm (n=12); attending individual session only (n=4); and failure to attend any of the intervention sessions (n=21).</p><p>Mixed model analyses of continuous scale end points used the residual maximum likelihood method to cope with missing values. Significance of the F-test for the group by time interaction is reported as well as t tests for the within-group changes over time and the between-group differences at each time. The proportion of participants in each group known to have achieved each of the dietary and physical activity goals at T1 and T3 was calculated, and the method of generalized estimating equations was used to fit models to enable group by time interactions to be tested (Wald &#x003c7;<sup>2</sup> test). The body weight goal (&#x02265;5% reduction at 12&#x02005;months) was assessed using a two-sample binomial test to compare the proportions in each group. The number of goals achieved by individuals at 12&#x02005;months was assessed using a mixed model analysis. Sensitivity analyses, in which missing assessments were deemed to indicate unmet goals, were conducted for each goal and also for the combined score. Unless otherwise stated, statistical tests were conducted at the 5% significance level without adjustments for multiplicity of either end points or comparisons.</p></sec><sec id="s1j"><title>Participants</title><p>In total, 2616 individuals were screened for eligibility, with 1067 having AUSDRISK score &#x02265;15. For various reasons, 725 people declined to participate. The ITT analysis set consisted of the remaining 342 participants&#x02014;177 intervention and 165 control arm (see online supplementary file 2&#x02014;CONSORT diagram). Major protocol deviations resulted in exclusion of further 44 participants. The PPS consisted of 298 participants&#x02014;143 intervention and 155 control arm.</p></sec><sec id="s1k"><title>Ethics</title><p>Deakin University Human Research Ethics Committee granted approval&#x02014;project code 2009-066. MDPS was registered with the Australian New Zealand Clinical Trial registry: ACTRN12609000507280.</p></sec></sec><sec sec-type="results" id="s2"><title>Results</title><p>Control and intervention arms had similar characteristics at baseline (<xref ref-type="table" rid="BMJDRC2015000131TB1">table 1</xref>). Overall mean age was 65&#x02005;years with 38% men. At baseline, 290 (84.8%) participants in the ITT had a FPG &#x02264;5.6&#x02005;mmol/L and 52 (15.2%) participants had a FPG 5.7&#x02013;6.9&#x02005;mmol/L (impaired fasting glucose). Similarly 281 (82.4%) participants in the ITT had a 2&#x02005;h OGTT glucose &#x02264;7.8&#x02005;mmol/L and n=60 (17.6%) had a 2&#x02005;h OGTT glucose 7.9&#x02013;11.0&#x02005;mmol/L (impaired glucose tolerance).</p><table-wrap id="BMJDRC2015000131TB1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of control participants, intervention participants, and all participants in the Melbourne Diabetes Prevention Study</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Control (n=165)</th><th align="left" rowspan="1" colspan="1">Intervention (n=177)</th><th align="left" rowspan="1" colspan="1">All participants (n=342)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (men)</td><td align="left" rowspan="1" colspan="1">61 (37.0%)</td><td align="left" rowspan="1" colspan="1">68 (38.4%)</td><td align="left" rowspan="1" colspan="1">129 (37.7%)</td></tr><tr><td colspan="4" rowspan="1">Age (years)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">165</td><td rowspan="1" colspan="1">177</td><td rowspan="1" colspan="1">342</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">65.0 (6.7)</td><td rowspan="1" colspan="1">65.1 (6.2)</td><td rowspan="1" colspan="1">65.0 (6.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">66.0</td><td rowspan="1" colspan="1">66.0</td><td rowspan="1" colspan="1">66.0</td></tr><tr><td colspan="4" rowspan="1">&#x02003;Age (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;0&#x02013;49</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">1 (0.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;50&#x02013;54</td><td rowspan="1" colspan="1">15 (9.1)</td><td rowspan="1" colspan="1">10 (5.6)</td><td rowspan="1" colspan="1">25 (7.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;55&#x02013;59</td><td rowspan="1" colspan="1">18 (10.9)</td><td rowspan="1" colspan="1">26 (14.7)</td><td rowspan="1" colspan="1">44 (12.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;60&#x02013;64</td><td rowspan="1" colspan="1">34 (20.6)</td><td rowspan="1" colspan="1">41 (23.2)</td><td rowspan="1" colspan="1">75 (21.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;65&#x02013;69</td><td rowspan="1" colspan="1">51 (30.9)</td><td rowspan="1" colspan="1">46 (26.0)</td><td rowspan="1" colspan="1">97 (28.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;70&#x02013;74</td><td rowspan="1" colspan="1">35 (21.2)</td><td rowspan="1" colspan="1">50 (28.2)</td><td rowspan="1" colspan="1">85 (24.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;75&#x02013;80</td><td rowspan="1" colspan="1">11 (6.7)</td><td rowspan="1" colspan="1">4 (2.3)</td><td rowspan="1" colspan="1">15 (4.4)</td></tr><tr><td colspan="4" rowspan="1">AUSDRISK</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">165</td><td rowspan="1" colspan="1">177</td><td rowspan="1" colspan="1">342</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">18.2 (3.2)</td><td rowspan="1" colspan="1">18.7 (3.5)</td><td rowspan="1" colspan="1">18.5 (3.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15&#x02013;19 (%)</td><td rowspan="1" colspan="1">121 (73.3)</td><td rowspan="1" colspan="1">118 (66.7)</td><td rowspan="1" colspan="1">239 (69.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;20 (%)</td><td rowspan="1" colspan="1">44 (26.6)</td><td rowspan="1" colspan="1">59 (33.3)</td><td rowspan="1" colspan="1">103 (30.1)</td></tr><tr><td colspan="4" rowspan="1">Framingham 5-year CVD risk</td></tr><tr><td colspan="4" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">294</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">8.3 (6.0)</td><td rowspan="1" colspan="1">9.4 (5.9)</td><td rowspan="1" colspan="1">8.8 (6.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">6.8</td><td rowspan="1" colspan="1">8.2</td><td rowspan="1" colspan="1">7.2</td></tr><tr><td colspan="4" rowspan="1">Waist (cm)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">177</td><td rowspan="1" colspan="1">340</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">102.5 (12.7)</td><td rowspan="1" colspan="1">101.7 (12.2)</td><td rowspan="1" colspan="1">102.1 (12.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">102.0</td><td rowspan="1" colspan="1">101.8</td><td rowspan="1" colspan="1">101.90</td></tr><tr><td colspan="4" rowspan="1">&#x02003;Waist (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;80</td><td rowspan="1" colspan="1">5 (3.1)</td><td rowspan="1" colspan="1">9 (5.1)</td><td rowspan="1" colspan="1">14 (4.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;80 to &#x0003c;90</td><td rowspan="1" colspan="1">21 (12.9)</td><td rowspan="1" colspan="1">23 (13.0)</td><td rowspan="1" colspan="1">44 (12.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;90 to &#x0003c;100</td><td rowspan="1" colspan="1">43 (26.4)</td><td rowspan="1" colspan="1">45 (25.4)</td><td rowspan="1" colspan="1">88 (25.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;100 to &#x0003c;110</td><td rowspan="1" colspan="1">51 (31.3)</td><td rowspan="1" colspan="1">54 (30.5)</td><td rowspan="1" colspan="1">105 (30.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;110 to &#x0003c;120</td><td rowspan="1" colspan="1">26 (16.0)</td><td rowspan="1" colspan="1">32 (18.1)</td><td rowspan="1" colspan="1">58 (17.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003e;120</td><td rowspan="1" colspan="1">17 (10.4)</td><td rowspan="1" colspan="1">14 (7.9)</td><td rowspan="1" colspan="1">31 (9.1)</td></tr><tr><td colspan="4" rowspan="1">BMI (kg/m<sup>2</sup>)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">177</td><td rowspan="1" colspan="1">340</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">31.34 (5.22)</td><td rowspan="1" colspan="1">31.16 (4.97)</td><td rowspan="1" colspan="1">31.25 (5.08)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;20 (%)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (0.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;20 to &#x0003c;25 (%)</td><td rowspan="1" colspan="1">11 (6.7)</td><td rowspan="1" colspan="1">14 (7.9)</td><td rowspan="1" colspan="1">25 (7.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;25 to &#x0003c;30 (%)</td><td rowspan="1" colspan="1">60 (36.8)</td><td rowspan="1" colspan="1">66 (37.3)</td><td rowspan="1" colspan="1">126 (37.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003e;30 (%)</td><td rowspan="1" colspan="1">91 (55.8)</td><td rowspan="1" colspan="1">97 (54.8)</td><td rowspan="1" colspan="1">188 (55.3)</td></tr><tr><td colspan="4" rowspan="1">Weight (kg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">177</td><td rowspan="1" colspan="1">340</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">87.4 (16.1)</td><td rowspan="1" colspan="1">86.5 (15.3)</td><td rowspan="1" colspan="1">87.0 (15.7)</td></tr><tr><td colspan="4" rowspan="1">Education (years)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">160</td><td rowspan="1" colspan="1">172</td><td rowspan="1" colspan="1">332</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">12.68 (3.09)</td><td rowspan="1" colspan="1">12.98 (3.88)</td><td rowspan="1" colspan="1">12.83 (3.51)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Primary (%)</td><td rowspan="1" colspan="1">49 (30.6)</td><td rowspan="1" colspan="1">55 (32.0)</td><td rowspan="1" colspan="1">104 (31.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Secondary (%)</td><td rowspan="1" colspan="1">45 (28.1)</td><td rowspan="1" colspan="1">56 (32.6)</td><td rowspan="1" colspan="1">101 (30.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Tertiary (%)</td><td rowspan="1" colspan="1">66 (41.3)</td><td rowspan="1" colspan="1">61 (35.5)</td><td rowspan="1" colspan="1">127 (38.3)</td></tr><tr><td colspan="4" rowspan="1">Income level</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">175</td><td rowspan="1" colspan="1">338</td></tr><tr><td rowspan="1" colspan="1">&#x02003;High (%)</td><td rowspan="1" colspan="1">87 (52.73)</td><td rowspan="1" colspan="1">89 (50.28)</td><td rowspan="1" colspan="1">176 (51.46)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Medium (%)</td><td rowspan="1" colspan="1">48 (29.09)</td><td rowspan="1" colspan="1">62 (35.03)</td><td rowspan="1" colspan="1">110 (32.16)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Low (%)</td><td rowspan="1" colspan="1">28 (16.97)</td><td rowspan="1" colspan="1">24 (13.56)</td><td rowspan="1" colspan="1">52 (15.20)</td></tr><tr><td colspan="4" rowspan="1">Smoking status</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">165</td><td rowspan="1" colspan="1">176</td><td rowspan="1" colspan="1">341</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-smoker (%)</td><td rowspan="1" colspan="1">155 (93.9)</td><td rowspan="1" colspan="1">162 (92.0)</td><td rowspan="1" colspan="1">317 (93.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Current smoker (%)</td><td rowspan="1" colspan="1">10 (6.1)</td><td rowspan="1" colspan="1">14 (8.0)</td><td rowspan="1" colspan="1">24 (7.0)</td></tr><tr><td colspan="4" rowspan="1">Work status</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">157</td><td rowspan="1" colspan="1">166</td><td rowspan="1" colspan="1">323</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Fulltime employed (%)</td><td rowspan="1" colspan="1">13 (7.9)</td><td rowspan="1" colspan="1">12 (6.9)</td><td rowspan="1" colspan="1">25 (7.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Part-time or casual employed (%)</td><td rowspan="1" colspan="1">30 (18.2)</td><td rowspan="1" colspan="1">34 (19.4)</td><td rowspan="1" colspan="1">64 (18.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unemployed and seeking work (%)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">3 (1.7)</td><td rowspan="1" colspan="1">4 (1.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Home duties (%)</td><td rowspan="1" colspan="1">19 (11.5)</td><td rowspan="1" colspan="1">13 (7.4)</td><td rowspan="1" colspan="1">32 (9.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Retired/pensioner (%)</td><td rowspan="1" colspan="1">90 (54.5)</td><td rowspan="1" colspan="1">103 (58.9)</td><td rowspan="1" colspan="1">193 (56.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Full-time carer (%)</td><td rowspan="1" colspan="1">4 (2.4)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">5 (1.5)</td></tr><tr><td colspan="4" rowspan="1">HADS-A</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">175</td><td rowspan="1" colspan="1">339</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Normal (&#x0003c;7) (%)</td><td rowspan="1" colspan="1">54 (32.9)</td><td rowspan="1" colspan="1">60 (34.3)</td><td rowspan="1" colspan="1">114 (33.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mild anxiety (8&#x02013;10) (%)</td><td rowspan="1" colspan="1">82 (50.0)</td><td rowspan="1" colspan="1">79 (45.1)</td><td rowspan="1" colspan="1">161 (47.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Moderate-severe anxiety (&#x02265;11) (%)</td><td rowspan="1" colspan="1">28 (17.1)</td><td rowspan="1" colspan="1">36 (20.6)</td><td rowspan="1" colspan="1">64 (18.9)</td></tr><tr><td colspan="4" rowspan="1">HADS-D</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">174</td><td rowspan="1" colspan="1">338</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Normal (&#x0003c;7) (%)</td><td rowspan="1" colspan="1">26 (15.9)</td><td rowspan="1" colspan="1">36 (20.7)</td><td rowspan="1" colspan="1">62 (18.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mild depression (8&#x02013;10) (%)</td><td rowspan="1" colspan="1">128 (78.0)</td><td rowspan="1" colspan="1">133 (76.4)</td><td rowspan="1" colspan="1">261 (77.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Moderate-severe depression (&#x02265;11) (%)</td><td rowspan="1" colspan="1">10 (6.1)</td><td rowspan="1" colspan="1">5 (2.9)</td><td rowspan="1" colspan="1">15 (4.4)</td></tr></tbody></table><table-wrap-foot><fn><p>BMI, body mass index; CVD, cardiovascular disease; HADS, hospital anxiety and depression score.</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="table" rid="BMJDRC2015000131TB2">Table&#x000a0;2</xref> presents the main outcome measure results of the PPS and ITT data sets. PPS results were considered more informative for the reasons outlined in the discussion, hence only the PPS results are given here.</p><table-wrap id="BMJDRC2015000131TB2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><p>Two-way table of predicted means (SEM) of time and group using ITT and the PPS</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Control</th><th align="left" rowspan="1" colspan="1">Intervention</th><th align="left" rowspan="1" colspan="1">Difference</th><th align="left" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><italic>PPS</italic></td></tr><tr><td colspan="5" rowspan="1">Weight (kg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">87.81 (1.36)</td><td rowspan="1" colspan="1">87.52 (1.36)</td><td rowspan="1" colspan="1">&#x02212;0.29</td><td rowspan="1" colspan="1">0.880</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">88.10 (1.36)</td><td rowspan="1" colspan="1">86.68 (1.36)</td><td rowspan="1" colspan="1">&#x02212;1.42</td><td rowspan="1" colspan="1">0.461</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">&#x02212;0.84</td><td rowspan="1" colspan="1">&#x02212;1.13</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.378</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.016*</td></tr><tr><td colspan="5" rowspan="1">Waist (cm)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">102.55 (1.07)</td><td rowspan="1" colspan="1">102.39 (1.07)</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">0.914</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">102.99 (1.07)</td><td rowspan="1" colspan="1">101.48 (1.07)</td><td rowspan="1" colspan="1">&#x02212;1.51</td><td rowspan="1" colspan="1">0.318</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.45</td><td rowspan="1" colspan="1">&#x02212;0.90</td><td rowspan="1" colspan="1">&#x02212;1.35</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.345</td><td rowspan="1" colspan="1">0.057</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.044*</td></tr><tr><td colspan="5" rowspan="1">FPG (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">5.09 (0.05)</td><td rowspan="1" colspan="1">5.16 (0.05)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.381</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">5.15 (0.05)</td><td rowspan="1" colspan="1">5.22 (0.05)</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.321</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.231</td><td rowspan="1" colspan="1">0.170</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.903*</td></tr><tr><td colspan="5" rowspan="1">OGTT 2&#x02005;h glucose</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">6.19 (0.16)</td><td rowspan="1" colspan="1">6.19 (0.16)</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.993</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">6.11 (0.16)</td><td rowspan="1" colspan="1">6.06 (0.16)</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">0.822</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.566</td><td rowspan="1" colspan="1">0.347</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.802*</td></tr><tr><td colspan="5" rowspan="1">Systolic (mm&#x02005;Hg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">139.89 (1.51)</td><td rowspan="1" colspan="1">144.14 (1.51)</td><td rowspan="1" colspan="1">4.25</td><td rowspan="1" colspan="1">0.049</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">137.75 (1.51)</td><td rowspan="1" colspan="1">136.83 (1.51)</td><td rowspan="1" colspan="1">&#x02212;0.92</td><td rowspan="1" colspan="1">0.666</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;2.14</td><td rowspan="1" colspan="1">&#x02212;7.31</td><td rowspan="1" colspan="1">&#x02212;5.17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.198</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.028*</td></tr><tr><td colspan="5" rowspan="1">Diastolic (mm&#x02005;Hg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">80.71 (0.98)</td><td rowspan="1" colspan="1">81.39 (0.98)</td><td rowspan="1" colspan="1">0.68</td><td rowspan="1" colspan="1">0.623</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">79.03 (0.98)</td><td rowspan="1" colspan="1">76.47 (0.98)</td><td rowspan="1" colspan="1">&#x02212;2.56</td><td rowspan="1" colspan="1">0.065</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;1.68</td><td rowspan="1" colspan="1">&#x02212;4.92</td><td rowspan="1" colspan="1">&#x02212;3.24</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.111</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.030*</td></tr><tr><td colspan="5" rowspan="1">Total cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">5.22 (0.09)</td><td rowspan="1" colspan="1">5.19 (0.09)</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.813</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">5.26 (0.09)</td><td rowspan="1" colspan="1">5.08 (0.09)</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">0.172</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.581</td><td rowspan="1" colspan="1">0.140</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.152*</td></tr><tr><td colspan="5" rowspan="1">Triglycerides (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">1.44 (0.05)</td><td rowspan="1" colspan="1">1.36 (0.05)</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">0.277</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">1.58 (0.05)</td><td rowspan="1" colspan="1">1.44 (0.05)</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">0.054</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.037</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.263*</td></tr><tr><td colspan="5" rowspan="1">LDL-cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">3.01 (0.08)</td><td rowspan="1" colspan="1">3.08 (0.08)</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.571</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">3.00 (0.08)</td><td rowspan="1" colspan="1">2.90 (0.08)</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">0.384</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.881</td><td rowspan="1" colspan="1">0.008</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.075*</td></tr><tr><td colspan="5" rowspan="1">HDL-cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">1.52 (0.04)</td><td rowspan="1" colspan="1">1.49 (0.04)</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.596</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">1.53 (0.04)</td><td rowspan="1" colspan="1">1.52 (0.04)</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.856</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.498</td><td rowspan="1" colspan="1">0.081</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.448*</td></tr><tr><td colspan="5" rowspan="1">Framingham 5-year CVD risk (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">8.35 (0.54)</td><td rowspan="1" colspan="1">9.72 (0.54)</td><td rowspan="1" colspan="1">1.37</td><td rowspan="1" colspan="1">0.075</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">8.46 (0.54)</td><td rowspan="1" colspan="1">8.75 (0.54)</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">0.704</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">&#x02212;0.97</td><td rowspan="1" colspan="1">&#x02212;1.08</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.712</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.013*</td></tr><tr><td colspan="5" rowspan="1"><italic>ITT</italic></td></tr><tr><td colspan="5" rowspan="1">Weight (kg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">87.35 (1.24)</td><td rowspan="1" colspan="1">86.53 (1.20)</td><td rowspan="1" colspan="1">&#x02212;0.82</td><td rowspan="1" colspan="1">0.636</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">87.61 (1.25)</td><td rowspan="1" colspan="1">85.95 (1.20)</td><td rowspan="1" colspan="1">&#x02212;1.67</td><td rowspan="1" colspan="1">0.337</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.26</td><td rowspan="1" colspan="1">&#x02212;0.59</td><td rowspan="1" colspan="1">&#x02212;0.85</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.451</td><td rowspan="1" colspan="1">0.079</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.079*</td></tr><tr><td colspan="5" rowspan="1">Waist (cm)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">102.46 (0.97)</td><td rowspan="1" colspan="1">101.72 (0.94)</td><td rowspan="1" colspan="1">&#x02212;0.74</td><td rowspan="1" colspan="1">0.584</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">102.87 (0.99)</td><td rowspan="1" colspan="1">101.13 (0.95)</td><td rowspan="1" colspan="1">&#x02212;1.74</td><td rowspan="1" colspan="1">0.205</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.41</td><td rowspan="1" colspan="1">&#x02212;0.59</td><td rowspan="1" colspan="1">&#x02212;1.00</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.379</td><td rowspan="1" colspan="1">0.187</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.122*</td></tr><tr><td colspan="5" rowspan="1">FPG (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">5.07 (0.05)</td><td rowspan="1" colspan="1">5.14 (0.04)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.328</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">5.14 (0.05)</td><td rowspan="1" colspan="1">5.19 (0.05)</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.514</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.122</td><td rowspan="1" colspan="1">0.236</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.763*</td></tr><tr><td colspan="5" rowspan="1">OGTT 2&#x02005;h glucose (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">6.18 (0.15)</td><td rowspan="1" colspan="1">6.19 (0.14)</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.983</td></tr><tr><td rowspan="1" colspan="1">12&#x02005;months</td><td rowspan="1" colspan="1">6.12 (0.15)</td><td rowspan="1" colspan="1">5.97 (0.15)</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">0.452</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.22</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.668</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.377*</td></tr><tr><td colspan="5" rowspan="1">Systolic BP (mm&#x02005;Hg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">140.23 (1.39)</td><td rowspan="1" colspan="1">143.00 (1.34)</td><td rowspan="1" colspan="1">2.77</td><td rowspan="1" colspan="1">0.152</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">137.57 (1.45)</td><td rowspan="1" colspan="1">136.34 (1.40)</td><td rowspan="1" colspan="1">&#x02212;1.22</td><td rowspan="1" colspan="1">0.544</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;2.66</td><td rowspan="1" colspan="1">&#x02212;6.65</td><td rowspan="1" colspan="1">&#x02212;3.99</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.091</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.068*</td></tr><tr><td colspan="5" rowspan="1">Diastolic BP (mm&#x02005;Hg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">80.89 (0.90)</td><td rowspan="1" colspan="1">81.33 (0.87)</td><td rowspan="1" colspan="1">0.44</td><td rowspan="1" colspan="1">0.725</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">78.65 (0.94)</td><td rowspan="1" colspan="1">76.32 (0.91)</td><td rowspan="1" colspan="1">&#x02212;2.33</td><td rowspan="1" colspan="1">0.076</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">&#x02212;2.24</td><td rowspan="1" colspan="1">&#x02212;5.01</td><td rowspan="1" colspan="1">&#x02212;2.77</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.046*</td></tr><tr><td colspan="5" rowspan="1">Total cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">5.23 (0.09)</td><td rowspan="1" colspan="1">5.21 (0.09)</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">0.877</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">5.28 (0.09)</td><td rowspan="1" colspan="1">5.14 (0.09)</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">0.263</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.12</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.452</td><td rowspan="1" colspan="1">0.308</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.212*</td></tr><tr><td colspan="5" rowspan="1">Triglycerides (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">1.43 (0.07)</td><td rowspan="1" colspan="1">1.49 (0.07)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.506</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">1.56 (0.07)</td><td rowspan="1" colspan="1">1.53 (0.07)</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.741</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.13</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">0.436</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.125*</td></tr><tr><td colspan="5" rowspan="1">LDL-cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">3.02 (0.08)</td><td rowspan="1" colspan="1">3.10 (0.07)</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.486</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">3.03 (0.08)</td><td rowspan="1" colspan="1">2.94 (0.08)</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">0.421</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.927</td><td rowspan="1" colspan="1">0.011</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.068*</td></tr><tr><td colspan="5" rowspan="1">HDL-cholesterol (mmol/L)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">1.52 (0.04)</td><td rowspan="1" colspan="1">1.52 (0.04)</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.951</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">1.53 (0.04)</td><td rowspan="1" colspan="1">1.55 (0.04)</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.760</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.601</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.336*</td></tr><tr><td colspan="5" rowspan="1">Framingham 5-year CVD risk (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Baseline</td><td rowspan="1" colspan="1">8.20 (0.46)</td><td rowspan="1" colspan="1">9.35 (0.44)</td><td rowspan="1" colspan="1">1.15</td><td rowspan="1" colspan="1">0.072</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12&#x02005;months</td><td rowspan="1" colspan="1">8.28 (0.45)</td><td rowspan="1" colspan="1">8.40 (0.44)</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.851</td></tr><tr><td rowspan="1" colspan="1">Difference</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">&#x02212;0.95</td><td rowspan="1" colspan="1">&#x02212;1.03</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">p Value</td><td rowspan="1" colspan="1">0.782</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.011*</td></tr></tbody></table><table-wrap-foot><fn><p>*p Value for the F-test of the time by group interaction.</p></fn><fn><p>BP, blood pressure; CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL, high-density lipoprotein; ITT, intention to treat; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; PPS, per protocol set.</p></fn></table-wrap-foot></table-wrap><p>At 12&#x02005;months in the PPS, the intervention group mean weight loss was 0.84&#x02005;kg but controls gained 0.29&#x02005;kg (mean difference 1.13&#x02005;kg; p=0.016). Similarly the intervention group mean waist circumference decreased by 0.90&#x02005;cm but controls increased by 0.45&#x02005;cm (mean difference 1.35&#x02005;cm; p=0.044). This 0.96% weight reduction predicts a 9.6% diabetes risk reduction. The intervention group reduced systolic BP by 7.3&#x02005;mm&#x02005;Hg and controls by 2.1&#x02005;mm&#x02005;Hg (mean difference 5.2&#x02005;mm&#x02005;Hg; p=0.028). A similar effect was seen in diastolic BP. The intervention group reduced diastolic BP by 4.9&#x02005;mm&#x02005;Hg and controls by 1.7&#x02005;mm&#x02005;Hg (mean difference 3.2&#x02005;mm&#x02005;Hg; p=0.030). There were no significant time&#x02013;arm interactions for FPG, OGTT 2&#x02005;h glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, or triglycerides.</p><p>In the analysis of the PPS for patients without established CVD, average 5-year Framingham absolute CVD risk decreased in the intervention group from 9.72% to 8.75% (p=0.002, 10.4% relative risk reduction), and increased in controls from 8.35% to 8.46% (p=0.712, 1.3% relative risk increase) resulting in a net effect of &#x02212;1.08% points of absolute risk. The interaction between time and study arm was statistically significant (p=0.013).</p><p>Using the PPS, the 3&#x02005;month intensive intervention phase showed statistically significant reductions in weight, waist, systolic and diastolic BP, and Framingham 5-year absolute risk compared with baseline for intervention participants. There was also a statistically significant increase in HDL-cholesterol (see online supplementary file 3). Between 3 and 12&#x02005;months, diastolic BP was reduced further and there were slight but non-significant increases in weight, systolic BP, and Framingham 5-year absolute risk. A significant increase of 1&#x02005;cm in waist circumference occurred between 3 and 12&#x02005;months.</p><p>In the PPS, the proportion of participants meeting the fiber intake goal increased from 20% (baseline) to 33% (12&#x02005;months) in the intervention arm, but there was no change in the control arm (p=0.028). A greater percentage of participants in the intervention group than in the control group achieved the 5% weight reduction goal (15% vs 8%; p=0.026). The total number of goals achieved at the conclusion of the study in the intervention group was higher than in the control group (1.26 vs 0.94; p=0.003). A similar conclusion held when missing goal assessments were assumed to be unmet goals (<xref ref-type="table" rid="BMJDRC2015000131TB3">table 3</xref>).</p><table-wrap id="BMJDRC2015000131TB3" orientation="portrait" position="float"><label>Table&#x000a0;3</label><caption><p>Proportions (%) of participants meeting the goals of the <italic>Life!</italic> programme at baseline and 12&#x02005;months, and total number of goals achieved at 12&#x02005;months for PPS and ITT</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">&#x000a0;Control</th><th align="left" rowspan="1" colspan="1">Intervention</th><th align="left" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><italic>PPS</italic></td></tr><tr><td colspan="4" rowspan="1">No more than 30% energy from fat</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">18/153 (11.76%)</td><td rowspan="1" colspan="1">11/143 (7.69%)</td><td rowspan="1" colspan="1">0.242</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">9/136 (6.62%)</td><td rowspan="1" colspan="1">14/138 (10.14%)</td><td rowspan="1" colspan="1">0.282</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.065</td><td rowspan="1" colspan="1">0.399</td><td rowspan="1" colspan="1">0.056*</td></tr><tr><td colspan="4" rowspan="1">No more than 10% energy from saturated fat</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">14/153 (9.15%)</td><td rowspan="1" colspan="1">6/143 (4.20%)</td><td rowspan="1" colspan="1">0.098</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">5/136 (3.68%)</td><td rowspan="1" colspan="1">8/138 (5.80%)</td><td rowspan="1" colspan="1">0.400</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.018</td><td rowspan="1" colspan="1">0.454</td><td rowspan="1" colspan="1">0.028*</td></tr><tr><td colspan="4" rowspan="1">At least 15&#x02005;g/1000&#x02005;kcal fiber intake</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">33/153 (21.57%)</td><td rowspan="1" colspan="1">29/143 (20.28%)</td><td rowspan="1" colspan="1">0.785</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">30/136 (22.06%)</td><td rowspan="1" colspan="1">46/138 (33.33%)</td><td rowspan="1" colspan="1">0.039</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.945</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.028*</td></tr><tr><td colspan="4" rowspan="1">At least 30&#x02005;min/day moderate intensity</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">75/145 (51.72%)</td><td rowspan="1" colspan="1">85/137 (62.04%)</td><td rowspan="1" colspan="1">0.074</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">71/133 (53.38%)</td><td rowspan="1" colspan="1">88/134 (65.67%)</td><td rowspan="1" colspan="1">0.039</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.729</td><td rowspan="1" colspan="1">0.456</td><td rowspan="1" colspan="1">0.757*</td></tr><tr><td colspan="4" rowspan="1">At least a 5% reduction in body weight</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Goal 5 (weight loss)</td><td rowspan="1" colspan="1">8/133 (6.0%)</td><td rowspan="1" colspan="1">19/134 (14.1%)</td><td rowspan="1" colspan="1">0.027</td></tr><tr><td colspan="4" rowspan="1">Mean total number of goals achieved&#x02020;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Control (n=129)</td><td align="left" rowspan="1" colspan="1">Intervention (n=133)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">1.29</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="4" rowspan="1">Mean total number of goals achieved&#x02021;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Control (n=154)</td><td align="left" rowspan="1" colspan="1">Intervention (n=143)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.79</td><td rowspan="1" colspan="1">1.22</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" rowspan="1"><italic>ITT</italic></td></tr><tr><td colspan="4" rowspan="1">No more than 30% energy from fat</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">21/162 (13.0%)</td><td rowspan="1" colspan="1">15/177 (8.5%)</td><td rowspan="1" colspan="1">0.185</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">12/146 (8.2%)</td><td rowspan="1" colspan="1">15/162 (9.3%)</td><td rowspan="1" colspan="1">0.702</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">0.785</td><td rowspan="1" colspan="1">0.153*</td></tr><tr><td colspan="4" rowspan="1">No more than 10% energy from saturated fat</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">16/162 (9.9%)</td><td rowspan="1" colspan="1">8/177 (4.5%)</td><td rowspan="1" colspan="1">0.061</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">7/146 (4.8%)</td><td rowspan="1" colspan="1">9/162 (5.6%)</td><td rowspan="1" colspan="1">0.777</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.029</td><td rowspan="1" colspan="1">0.668</td><td rowspan="1" colspan="1">0.079*</td></tr><tr><td colspan="4" rowspan="1">At least 15&#x02005;g/1000&#x02005;kcal fiber intake</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">34/162 (21.0%)</td><td rowspan="1" colspan="1">36/177 (20.3%)</td><td rowspan="1" colspan="1">0.894</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">31/146 (21.2%)</td><td rowspan="1" colspan="1">52/162 (32.1%)</td><td rowspan="1" colspan="1">0.034</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.971</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.035*</td></tr><tr><td colspan="4" rowspan="1">At least 30&#x02005;min/day moderate intensity</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T1</td><td rowspan="1" colspan="1">80/154 (52.0%)</td><td rowspan="1" colspan="1">106/169 (62.7%)</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td rowspan="1" colspan="1">&#x02003;T3</td><td rowspan="1" colspan="1">75/142 (52.8%)</td><td rowspan="1" colspan="1">98/156 (62.8%)</td><td rowspan="1" colspan="1">0.079</td></tr><tr><td rowspan="1" colspan="1">&#x02003;p Value</td><td rowspan="1" colspan="1">0.861</td><td rowspan="1" colspan="1">0.912</td><td rowspan="1" colspan="1">0.840*</td></tr><tr><td colspan="4" rowspan="1">At least a 5% reduction in body weight</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Goal 5 (weight loss)</td><td rowspan="1" colspan="1">11/143 (7.7%)</td><td rowspan="1" colspan="1">24/157 (15.3%)</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td colspan="4" rowspan="1">Mean total number of goals achieved&#x02020;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Control (n=139)</td><td align="left" rowspan="1" colspan="1">Intervention (n=154)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">1.25</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td colspan="4" rowspan="1">Mean total number of goals achieved&#x02021;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Control (n=165)</td><td align="left" rowspan="1" colspan="1">Intervention (n=177)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.82</td><td rowspan="1" colspan="1">1.12</td><td rowspan="1" colspan="1">0.005</td></tr></tbody></table><table-wrap-foot><fn><p>*p Value for the Wald &#x003c7;<sup>2</sup> test of the time by group interaction.</p></fn><fn><p>&#x02020;Participants with one or more missing data excluded.</p></fn><fn><p>&#x02021;Missing data replaced with non-achievement of goal.</p></fn><fn><p>IIT, intention to treat; PPS, per protocol set.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions" id="s3"><title>Conclusions</title><p>This is the first report of an evaluation for a scaled-up diabetes prevention programme using an RCT. The MDPS was an effectiveness trial linked to the statewide, translational diabetes prevention programme <italic>Life!</italic> in Victoria, Australia. In the PPS analysis after 12&#x02005;months, MDPS showed significant improvements in weight, waist, BP, and CVD risk in the intervention group compared with usual care. Diabetes risk was also reduced. A statistically significant CVD risk reduction between baseline and 12&#x02005;months was shown in the intervention group with no change in the control group. The intervention group CVD risk reduction resulted mainly from a considerable BP reduction, which was not explained by any single factor, such as weight loss, physical activity, or medication changes, between baseline and 12&#x02005;months. The improvement in BP is likely to be multifactorial with exercise, weight loss, reduced salt intake, and medication all having contributory effects.</p><p>MDPS showed a smaller intervention effect compared with some other trials, possibly because lower baseline risk meant there was less scope for improvement in health measures.<xref rid="R6" ref-type="bibr">6</xref>
<xref rid="R12" ref-type="bibr">12</xref> A similar effect was seen in FIN D2D which was a real-world scaled-up programme run in Finnish primary healthcare.<xref rid="R9" ref-type="bibr">9</xref> However, even a modest 1&#x02005;kg weight reduction can reduce diabetes risk by 16%.<xref rid="R32" ref-type="bibr">32</xref></p><p><italic>Life!</italic> is the second scaled-up diabetes prevention programme to be reported, after the FIN D2D programme. Several randomized efficacy trials demonstrated that lifestyle modification interventions are effective in reducing T2DM risk.<xref rid="R2" ref-type="bibr">2&#x02013;4</xref> Many translational &#x02018;real-world&#x02019; diabetes prevention programmes have also demonstrated positive results, but they were all small scale.<xref rid="R6" ref-type="bibr">6</xref> Once high-risk individuals attend the interventions, and especially if the intervention dose is large enough, they benefit remarkably from lifestyle modification.<xref rid="R6" ref-type="bibr">6</xref> Furthermore, participants from all socioeconomic groups seem to benefit equally.<xref rid="R34" ref-type="bibr">34</xref> What has been missing is the rigor of an RCT, in real-world, scaled-up settings to measure impact.</p><sec id="s3a"><title>Public health interventions and ITT analysis</title><p>Although some would see ITT as the gold standard for reporting real-world diabetes prevention programmes, not all studies included in the recent systematic review reported ITT.<xref rid="R6" ref-type="bibr">6</xref> In MDPS, a single intervention participant who gained 20&#x02005;kg contributed to the non-significant effect in the ITT analysis. If he was excluded from analysis, weight reduction changes from p=0.079 to 0.026. The PPS analysis excluded this participant (prior to statistician unblinding) because he did not attend any intervention sessions. The PPS analysis relates to an idealized situation and demonstrates what the benefits can be for willing participants. Health services planning is based on those who are prepared to participate in an intervention. By presenting both ITT and PPS data, we aim to show a fuller picture.</p></sec><sec id="s3b"><title>Programme drift</title><p>A major concern about real-world diabetes prevention programmes is the extent of benefit delivered over extended time periods, particularly important given the long-term payback on investment. Programme drift denotes deviation from protocol resulting in a reduced effect, and it is potentially an important cause of attenuated effect.<xref rid="R17" ref-type="bibr">17</xref></p><p>In common with diabetes prevention programmes generally, recruiting difficulties for MDPS were a challenge from the outset.<xref rid="R35" ref-type="bibr">35</xref> Most participants were recruited during a brief contact in pharmacies and followed up by the study nurses. The recorded reasons for not proceeding to baseline testing were: no longer being interested, meeting exclusion criteria, AUSDRISK being below threshold on checking, living too far from the intervention, or becoming ill. After baseline testing, MDPS attrition rate was low mainly because the same nurse was involved in all participant contacts through to the final testing, multiple contact methods were used and the nurses were persistent. Similarly, recruitment into <italic>Life!</italic> was initially challenging and led to ongoing modifications of the programme to respond to that challenge.<xref rid="R10" ref-type="bibr">10</xref> This raises issues about motivating high-risk individuals to participate in such programmes, in order for the programmes to improve their effect, and ensure their future sustainability. Another example of programme drift in MDPS (and <italic>Life!</italic>) was that intervention participant weight and waist circumference did not continue to reduce between 3 and 12&#x02005;months (see online supplementary file 3), unlike in the original GGT DPP.<xref rid="R9" ref-type="bibr">9</xref> The MDPS intervention dose was lower in terms of number of sessions included and time allocated to self-monitoring tools feedback, for example, food and physical activity diaries.<xref rid="R12" ref-type="bibr">12</xref> This reduction potentially decreased the level of social support and intervention intensity experienced by participants.<xref rid="R36" ref-type="bibr">36</xref> Providing individualized risk feedback is important and more likely to result in behavior change than generalized feedback.<xref rid="R37" ref-type="bibr">37</xref> A recent systematic review described the importance of intervention intensity and fidelity for achieving positive outcomes.<xref rid="R6" ref-type="bibr">6</xref></p></sec><sec id="s3c"><title>Voltage drop</title><p>Voltage drop denotes the reduced benefits of diabetes prevention programmes when they move from efficacy trials to the real world. Voltage drop in MDPS (and <italic>Life!</italic>) might largely be explained by participant screening using AUSDRISK. MDPS baseline weight, waist, lipids, and glucose measures were all noticeably lower than in GGT DPP,<xref rid="R12" ref-type="bibr">12</xref> and MDPS participants were 10&#x02005;years older. Relatively low baseline diabetes risk might also explain the absence of changes in glucose measures. Participants at low risk would have become aware of this fact during their first session, which may have reduced their motivation for lifestyle modification. Mean AUSDRISK score for MDPS participants was 18.5 corresponding to a risk of one in seven developing T2DM. In our earlier GGT DPP, mean FINDRISC score of participants was 15.7 corresponding to a higher risk of one in three.<xref rid="R12" ref-type="bibr">12</xref> These results raise the question about which entry score to use for identifying high-risk individuals for admission into interventions. We note in our cohort that BP and cholesterol were lower than the GGT DPP<xref rid="R12" ref-type="bibr">12</xref> and Finnish DPS<xref rid="R4" ref-type="bibr">4</xref> at baseline. This is the first report comparing AUSDRISK&#x02019;s performance in a lifestyle modification intervention trial. AUSDRISK entry score was established by the Council of Australian Governments for use by all state and federally funded programmes, including the <italic>Life!</italic> programme, with a score &#x02265;15 indicating high risk of developing diabetes (1 in 7 risk). Subsequently eligibility for <italic>Life!</italic> changed to a score &#x02265;12 which is equal to a 1 in 14 risk of developing diabetes. High BMI is a significant predictor of T2DM, but BMI is not included in AUSDRISK. FINDRISC includes both BMI and waist circumference. Furthermore, as AUSDRISK is heavily loaded for age, male gender, and other non-modifiable risk factors, even AUSDRISK score &#x02265;20 can still result in participants entering programmes with only non-modifiable risk factors detected.</p><p>Screening into diabetes prevention programmes in the real world usually includes a glucose metabolism indicator as an entry criterion.<xref rid="R6" ref-type="bibr">6</xref> FPG has been shown to strongly improve the performance of risk prediction models based on non-invasive measures (routinely collected data or questionnaire data).<xref rid="R38" ref-type="bibr">38</xref> Based on this evidence and our findings, we recommend that a glucose metabolism measure be used in conjunction with a diabetes risk score when screening for high-risk individuals to enter into diabetes prevention programmes. The obligatory use of AUSDRISK is an example of voltage drop caused by real world, an unintended adverse consequence of government policy.</p><p>Consequently, there are lessons about hazards of developing new risk assessment tools rather than using the internationally well-established FINDRISC.<xref rid="R39" ref-type="bibr">39</xref> In the only other reported scaled-up diabetes prevention programme, FIN D2D, the entry criterion was set at a FINDRISC score &#x02265;15<xref rid="R9" ref-type="bibr">9</xref> which is equivalent to 20 on the AUSDRISK. Rather than overwhelm health services, the Finnish government decided to only take those at highest risk, as approximately 30% of the population aged 50&#x02005;years or over is at moderate-to-high risk of developing T2DM.<xref rid="R40" ref-type="bibr">40</xref> The current AUSDRISK score for entry into diabetes prevention programmes needs to be revised.</p></sec><sec id="s3d"><title>Strengths, limitations and implications</title><p>Using an RCT with well-matched intervention and control groups, we critically investigated a real-world, scaled-up implementation of a diabetes prevention programme in order to learn more about effectiveness. We have provided recommendations on how the <italic>Life!</italic> programme can be improved. The main difficulty of the MDPS appears to relate to recruitment being considerably less than originally intended. Potential participants were more willing to be recruited to the <italic>Life!</italic> programme or be recommended to the <italic>Life!</italic> programme by their GPs than to take the perceived risk of being in the control group of the RCT. Additionally, the MDPS participants were older, with a higher proportion retired, and having smaller waist circumferences than those in <italic>Life!</italic>, limiting the effect the intervention might have.</p><p>Challenges during the enrolment phase and funding constraints resulted in the recruitment of 342 participants (177 intervention and 165 control) out of an initial target of 796 (398 per arm). With the reduced numbers, the trial was still powered to detect small-to-moderate effect sizes for diastolic BP, 2&#x02005;h OGTT, total cholesterol, LDL, weight, and waist circumference. At this sample size, the trial was underpowered to detect differences in FPG, triglycerides, systolic BP, and diastolic BP&#x02014;noting that the two BP measures were significant when testing the group by time interaction.</p><p>This study's strength was the rigorous methodology for MDPS data collection compared with the data collected in <italic>Life!</italic> For example, MDPS weight and waist circumference were performed by study nurses who used strict protocols. In <italic>Life!</italic> facilitators perform the measures with no external verification of data accuracy. These strengths and limitations may explain much of the difference in effect size between MDPS and <italic>Life!</italic><xref rid="R10" ref-type="bibr">10</xref></p><p>Building a sustainable health promotion programme requires long-term financing, workforce training, supervision, and organizational support. The benefits of engaging in ongoing development, evaluation, and refinement of programmes should show as increased effects, improved quality, or both.<xref rid="R17" ref-type="bibr">17</xref> Based on this study, the <italic>Life!</italic> programme could apply quality improvement strategies to the intervention to achieve better impact and sustainability.</p><p>This study highlights the need to identify and recruit participants more likely to benefit from lifestyle modification programmes. When scaling-up diabetes prevention programmes in the real world, maintaining fidelity to the original components is an essential requirement, along with the need for ongoing accurate data collection to facilitate quality improvement aimed at enhancing sustainability and effect.</p></sec></sec></body><back><ack><p>The authors would like to acknowledge the Victorian Government Department of Health Victoria who funded the <italic>Life! Taking action on diabetes</italic> programme and Professor Greg Johnson and Dr Amy Timoshanko at Diabetes Australia Victoria for implementing <italic>Life!</italic>, as well as MDPS project team members: Trish Clark, Dino Asproloupos, Jessica Bucholc, Jacinta Sharpe, Caddie Conroy, Carol Wildey, Jessica Webster, Denise van den Bosch, Vicky Cogley, Clare D'Onofrio, Anne Bruce, Candy De Souza, Andrew Dalton, Lisa Mighall, Maya Rivis, Kate Delley, Thili Chengodu, Annette Bond, Chris Schouler, Jieling Li, Greater Eastern Primary Health, Sarah Bowman, Ben Philpot, Vicki Brown, Dr Nathalie Davis, Natasha Sciotto, and Su Neuling.</p></ack><fn-group><fn><p><bold>Contributors:</bold> JAD, EDJ, and RC were responsible for the research question, design of the study, and for obtaining funding. JAD, ALH, VLV, EV, and TL wrote the first draft of this manuscript. ALH and VLV were responsible for the revisions, along with EDJ and JDB. JR, VLV, and MC undertook the data analysis. JDB, TCS, SLO, KPM, ES, and CMB contributed to specific sections of the manuscript. All authors read and approved the final version of the manuscript.</p></fn><fn><p><bold>Funding:</bold> This study was funded by the National Health and Medical Research Council, grant number: 533819.</p></fn><fn><p><bold>Competing interests:</bold> None declared.</p></fn><fn><p><bold>Patient consent:</bold> Obtained.</p></fn><fn><p><bold>Ethics approval:</bold> Human Ethics Unit Research Integrity Office, Research Services Division, Deakin University CRICOS Provider Code 00113B (Vic).</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn><p><bold>Data sharing statement:</bold> No additional data are available.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guariguata</surname><given-names>L</given-names></name>, <name><surname>Whiting</surname><given-names>DR</given-names></name>, <name><surname>Hambleton</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Global estimates of diabetes prevalence for 2013, projections for 2035</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2014</year>;<volume>103</volume>:<fpage>137</fpage>&#x02013;<lpage>49</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.diabres.2013.11.002">doi:10.1016/j.diabres.2013.11.002</ext-link><pub-id pub-id-type="pmid">24630390</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name>, <name><surname>Barrett-Connor</surname><given-names>E</given-names></name>, <name><surname>Fowler</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>. <source>N Engl J Med</source>
<year>2002</year>;<volume>346</volume>:<fpage>393</fpage>&#x02013;<lpage>403</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa012512">doi:10.1056/NEJMoa012512</ext-link><pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>XR</given-names></name>, <name><surname>Li</surname><given-names>GW</given-names></name>, <name><surname>Hu</surname><given-names>YH</given-names></name><etal/></person-group>
<article-title>Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>537</fpage>&#x02013;<lpage>44</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/diacare.20.4.537">doi:10.2337/diacare.20.4.537</ext-link><pub-id pub-id-type="pmid">9096977</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>J</given-names></name>, <name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Eriksson</surname><given-names>JG</given-names></name><etal/></person-group>
<collab>For the Finnish Diabetes Prevention Study Group</collab>. <article-title>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</article-title>. <source>N Engl J Med</source>
<year>2001</year>;<volume>344</volume>:<fpage>1343</fpage>&#x02013;<lpage>50</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM200105033441801">doi:10.1056/NEJM200105033441801</ext-link><pub-id pub-id-type="pmid">11333990</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Peltonen</surname><given-names>M</given-names></name>, <name><surname>Eriksson</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)</article-title>. <source>Diabetologia</source>
<year>2013</year>;<volume>56</volume>:<fpage>284</fpage>&#x02013;<lpage>93</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00125-012-2752-5">doi:10.1007/s00125-012-2752-5</ext-link><pub-id pub-id-type="pmid">23093136</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunkley</surname><given-names>AJ</given-names></name>, <name><surname>Bodicoat</surname><given-names>DH</given-names></name>, <name><surname>Greaves</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis</article-title>. <source>Diabetes Care</source>
<year>2014</year>;<volume>37</volume>:<fpage>922</fpage>&#x02013;<lpage>33</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc13-2195">doi:10.2337/dc13-2195</ext-link><pub-id pub-id-type="pmid">24652723</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Neumann</surname><given-names>A</given-names></name>, <name><surname>Sheppard</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Take action to prevent diabetes&#x02014;the IMAGE toolkit for the prevention of type 2 diabetes in Europe</article-title>. <source>Horm Metab Res</source>
<year>2010</year>;<volume>42</volume>:<fpage>S37</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-0029-1240975">doi:10.1055/s-0029-1240975</ext-link><pub-id pub-id-type="pmid">20391307</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulweber</surname><given-names>B</given-names></name>, <name><surname>Valensi</surname><given-names>P</given-names></name>, <name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A European evidence-based guideline for the prevention of type 2 diabetes</article-title>. <source>Horm Metab Res</source>
<year>2010</year>;<volume>42</volume>:<fpage>S3</fpage>&#x02013;<lpage>36</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1055/s-0029-1240928">doi:10.1055/s-0029-1240928</ext-link><pub-id pub-id-type="pmid">20391306</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saaristo</surname><given-names>T</given-names></name>, <name><surname>Moilanen</surname><given-names>L</given-names></name>, <name><surname>Korpi-Hy&#x000f6;v&#x000e4;lti</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D)</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>2146</fpage>&#x02013;<lpage>51</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc10-0410">doi:10.2337/dc10-0410</ext-link><pub-id pub-id-type="pmid">20664020</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>JA</given-names></name>, <name><surname>Jayawardena</surname><given-names>A</given-names></name>, <name><surname>Johnson</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Scaling up diabetes prevention in Victoria, Australia: policy development, implementation, and evaluation</article-title>. <source>Diabetes Care</source>
<year>2014</year>;<volume>37</volume>:<fpage>934</fpage>&#x02013;<lpage>42</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc12-2647">doi:10.2337/dc12-2647</ext-link><pub-id pub-id-type="pmid">24319121</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Absetz</surname><given-names>P</given-names></name>, <name><surname>Valve</surname><given-names>R</given-names></name>, <name><surname>Oldenberg</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Type 2 diabetes prevention in the &#x0201c;real world&#x0201d;: one-year results of the GOAL implementation trial</article-title>. <source>Diabetes Care</source>
<year>2007</year>;<volume>30</volume>:<fpage>2465</fpage>&#x02013;<lpage>70</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc07-0171">doi:10.2337/dc07-0171</ext-link><pub-id pub-id-type="pmid">17586741</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laatikainen</surname><given-names>T</given-names></name>, <name><surname>Dunbar</surname><given-names>J</given-names></name>, <name><surname>Chapman</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project</article-title>. <source>BMC Public Health</source>
<year>2007</year>;<volume>7</volume>:<fpage>249</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-7-249">doi:10.1186/1471-2458-7-249</ext-link><pub-id pub-id-type="pmid">17877832</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasgow</surname><given-names>RE</given-names></name>, <name><surname>Lichtenstein</surname><given-names>E</given-names></name>, <name><surname>Marcus</surname><given-names>AC</given-names></name></person-group>
<article-title>Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition</article-title>. <source>Am J Public Health</source>
<year>2003</year>;<volume>93</volume>:<fpage>1261</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2105/AJPH.93.8.1261">doi:10.2105/AJPH.93.8.1261</ext-link><pub-id pub-id-type="pmid">12893608</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bero</surname><given-names>LA</given-names></name>, <name><surname>Grilli</surname><given-names>R</given-names></name>, <name><surname>Grimshaw</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings</article-title>. <source>BMJ</source>
<year>1998</year>;<volume>317</volume>:<fpage>465</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.317.7156.465">doi:10.1136/bmj.317.7156.465</ext-link><pub-id pub-id-type="pmid">9703533</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetler</surname><given-names>CB</given-names></name>, <name><surname>McQueen</surname><given-names>L</given-names></name>, <name><surname>Demakis</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>An organizational framework and strategic implementation for system-level change to enhance research-based practice: QUERI Series</article-title>. <source>Implement Sci</source>
<year>2008</year>;<volume>3</volume>:<fpage>30</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1748-5908-3-30">doi:10.1186/1748-5908-3-30</ext-link><pub-id pub-id-type="pmid">18510750</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>DH</given-names></name>, <name><surname>Adam</surname><given-names>T</given-names></name>, <name><surname>Alonge</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Implementation research: what it is and how to do it</article-title>. <source>BMJ</source>
<year>2013</year>;<volume>347</volume>:<fpage>f6753</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.f7086">doi:10.1136/bmj.f7086</ext-link><pub-id pub-id-type="pmid">24259324</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>D</given-names></name>, <name><surname>Glasgow</surname><given-names>R</given-names></name>, <name><surname>Stange</surname><given-names>K</given-names></name></person-group>
<article-title>The dynamic sustainability framework: addressing the paradox of sustainment amid ongoing change</article-title>. <source>Implement Sci</source>
<year>2013</year>;<volume>8</volume>:<fpage>117</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1748-5908-8-117">doi:10.1186/1748-5908-8-117</ext-link><pub-id pub-id-type="pmid">24088228</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis-Lameloise</surname><given-names>N</given-names></name>, <name><surname>Hernan</surname><given-names>A</given-names></name>, <name><surname>Janus</surname><given-names>ED</given-names></name><etal/></person-group>
<article-title>The Melbourne Diabetes Prevention Study (MDPS): study protocol for a randomized controlled trial</article-title>. <source>Trials</source>
<year>2013</year>;<volume>14</volume>:<fpage>31</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1745-6215-14-31">doi:10.1186/1745-6215-14-31</ext-link><pub-id pub-id-type="pmid">23369724</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Magliano</surname><given-names>D</given-names></name>, <name><surname>Balkau</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures</article-title>. <source>Med J Aust</source>
<year>2010</year>;<volume>192</volume>:<fpage>197</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">20170456</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bandura</surname><given-names>A</given-names></name></person-group>
<source>Self-efficacy: the exercise of control</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Freeman</publisher-name>, <year>1997</year>.</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>R</given-names></name></person-group>
<article-title>Self-efficacy in the adoption and maintenance of health behaviors: theoretical approaches and a new model</article-title>. In: <person-group person-group-type="editor"><name><surname>Schwarzer</surname><given-names>R</given-names></name></person-group>, ed. <source>Self-efficacy: thought control of action</source>. <publisher-loc>Washington DC</publisher-loc>: <publisher-name>Hemisphere</publisher-name>, <year>1992</year>:<fpage>217</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>R</given-names></name>, <name><surname>Fuchs</surname><given-names>R</given-names></name></person-group>
<article-title>Self efficacy and health behaviors</article-title>. In: <person-group person-group-type="editor"><name><surname>Connor</surname><given-names>M</given-names></name>, <name><surname>Norman</surname><given-names>P</given-names></name></person-group>, eds. <source>Predicting health behavior: research and practice with social cognition models</source>. <publisher-loc>Buckingham, UK</publisher-loc>: <publisher-name>Open University Press</publisher-name>, <year>1996</year>:<fpage>163</fpage>&#x02013;<lpage>96</lpage>.</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tolonen</surname><given-names>H</given-names></name>, <name><surname>Kuulasmaa</surname><given-names>K</given-names></name>, <name><surname>Laatikainen</surname><given-names>T</given-names></name><etal/></person-group>
<collab>European Health Risk Monitoring Project</collab><source>. <italic>Recommendation for indicators, international collaboration, protocol and manual of operations for chronic disease risk factor surveys</italic></source>. <publisher-name>Helsinki, Finnish National Public Health Institute</publisher-name>, <year>2002</year>.</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><comment>[No authors listed]</comment>
<article-title>The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. WHO MONICA Project Principal Investigators</article-title>. <source>J Clin Epidemiol</source>
<year>1988</year>;<volume>41</volume>:<fpage>105</fpage>&#x02013;<lpage>14</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0895-4356(88)90084-4">doi:10.1016/0895-4356(88)90084-4</ext-link><pub-id pub-id-type="pmid">3335877</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>A</given-names></name>, <name><surname>Patterson</surname><given-names>AJ</given-names></name>, <name><surname>Brown</surname><given-names>WJ</given-names></name><etal/></person-group>
<article-title>The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation</article-title>. <source>Aust N Z J Public Health</source>
<year>2000</year>;<volume>24</volume>:<fpage>576</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1467-842X.2000.tb00520.x">doi:10.1111/j.1467-842X.2000.tb00520.x</ext-link><pub-id pub-id-type="pmid">11215004</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="book"><collab>Australian Institute of Health and Welfare</collab>. <source>The Active Australia Survey: a guide and manual for implementation, analysis and reporting</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>AIHW</publisher-name>, <year>2003</year>.</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruthur</surname><given-names>N</given-names></name>, <name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Delahanty</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Early response to preventive strategies in the Diabetes Prevention Program</article-title>. <source>J Gen Intern Med</source>
<year>2013</year>;<volume>28</volume>:<fpage>1629</fpage>&#x02013;<lpage>36</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11606-013-2548-4">doi:10.1007/s11606-013-2548-4</ext-link><pub-id pub-id-type="pmid">23860722</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janus</surname><given-names>E</given-names></name>, <name><surname>Best</surname><given-names>JD</given-names></name>, <name><surname>Davis-Lameloise</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Scaling-up from an implementation trial to state-wide coverage: results from the preliminary Melbourne Diabetes Prevention Study</article-title>. <source>Trials</source>
<year>2012</year>;<volume>13</volume>:<fpage>152</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1745-6215-13-152">doi:10.1186/1745-6215-13-152</ext-link><pub-id pub-id-type="pmid">22929458</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Peltonen</surname><given-names>M</given-names></name>, <name><surname>Tuomilehto</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lifestyle strategies for weight control: experience from the Finnish Diabetes Prevention Study</article-title>. <source>Proc Nutr Soc</source>
<year>2005</year>;<volume>64</volume>:<fpage>81</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1079/PNS2004412">doi:10.1079/PNS2004412</ext-link><pub-id pub-id-type="pmid">15877926</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penn</surname><given-names>L</given-names></name>, <name><surname>White</surname><given-names>M</given-names></name>, <name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e57143</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0057143">doi:10.1371/journal.pone.0057143</ext-link><pub-id pub-id-type="pmid">23451166</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>RC</given-names></name>, <name><surname>Cooper</surname><given-names>AR</given-names></name>, <name><surname>Montgomery</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>378</volume>:<fpage>129</fpage>&#x02013;<lpage>39</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(11)60442-X">doi:10.1016/S0140-6736(11)60442-X</ext-link><pub-id pub-id-type="pmid">21705068</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamman</surname><given-names>RF</given-names></name>, <name><surname>Wing</surname><given-names>RR</given-names></name>, <name><surname>Edelstein</surname><given-names>SL</given-names></name><etal/></person-group>
<article-title>Effect of weight loss with lifestyle intervention on risk of diabetes</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>2102</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/dc06-0560">doi:10.2337/dc06-0560</ext-link><pub-id pub-id-type="pmid">16936160</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>K</given-names></name>, <name><surname>Odell</surname><given-names>P</given-names></name>, <name><surname>Wilson</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Cardiovascular disease risk profiles</article-title>. <source>Am Heart J</source>
<year>1991</year>;<volume>121</volume>:<fpage>293</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0002-8703(91)90861-B">doi:10.1016/0002-8703(91)90861-B</ext-link><pub-id pub-id-type="pmid">1985385</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hankonen</surname><given-names>N</given-names></name>, <name><surname>Absetz</surname><given-names>P</given-names></name>, <name><surname>Haukkala</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Socioeconomic status and psychosocial mechanisms of lifestyle change in a type 2 diabetes prevention trial</article-title>. <source>Ann Behav Med</source>
<year>2009</year>;<volume>38</volume>:<fpage>160</fpage>&#x02013;<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12160-009-9144-1">doi:10.1007/s12160-009-9144-1</ext-link><pub-id pub-id-type="pmid">19997790</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>JA</given-names></name>, <name><surname>Hernan</surname><given-names>A</given-names></name>, <name><surname>Janus</surname><given-names>ED</given-names></name><etal/></person-group>
<article-title>Implementation salvage experiences from the Melbourne diabetes prevention study</article-title>. <source>BMC Public Health</source>
<year>2012</year>;<volume>12</volume>:<fpage>806</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2458-12-806">doi:10.1186/1471-2458-12-806</ext-link><pub-id pub-id-type="pmid">22992417</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laatikainen</surname><given-names>T</given-names></name>, <name><surname>Philpot</surname><given-names>B</given-names></name>, <name><surname>Hankonen</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Predicting changes in lifestyle and clinical outcomes in preventing diabetes: the Greater Green Triangle Diabetes Prevention Project</article-title>. <source>Prev Med</source>
<year>2011</year>;<volume>54</volume>:<fpage>157</fpage>&#x02013;<lpage>61</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ypmed.2011.12.015">doi:10.1016/j.ypmed.2011.12.015</ext-link><pub-id pub-id-type="pmid">22227224</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>A</given-names></name>, <name><surname>Unigwe</surname><given-names>S</given-names></name>, <name><surname>Elwyn</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Effects of communicating individual risks in screening programmes: Cochrane systematic review</article-title>. <source>BMJ</source>
<year>2003</year>;<volume>327</volume>:<fpage>703</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.327.7417.703">doi:10.1136/bmj.327.7417.703</ext-link><pub-id pub-id-type="pmid">14512475</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buijsse</surname><given-names>B</given-names></name>, <name><surname>Simmons</surname><given-names>RK</given-names></name>, <name><surname>Griffin</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Risk assessment tools for identifying individuals at risk of developing type 2 diabetes</article-title>. <source>Epidemiol Rev</source>
<year>2011</year>;<volume>33</volume>:<fpage>46</fpage>&#x02013;<lpage>62</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/epirev/mxq019">doi:10.1093/epirev/mxq019</ext-link><pub-id pub-id-type="pmid">21622851</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alssema</surname><given-names>M</given-names></name>, <name><surname>Vistisen</surname><given-names>D</given-names></name>, <name><surname>Heymans</surname><given-names>MW</given-names></name><etal/></person-group>
<article-title>The evaluation of screening and early detection strategies for type 2 diabetes and impaired glucose tolerance (DETECT-2) update of the Finnish diabetes risk score for prediction of incident type 2 diabetes</article-title>. <source>Diabetologia</source>
<year>2011</year>;<volume>54</volume>:<fpage>1004</fpage>&#x02013;<lpage>12</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00125-010-1990-7">doi:10.1007/s00125-010-1990-7</ext-link><pub-id pub-id-type="pmid">21153531</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heinonen</surname><given-names>K</given-names></name>, <name><surname>Syv&#x000e4;nne</surname><given-names>M</given-names></name>, <name><surname>Toropainen</surname><given-names>E</given-names></name><etal/></person-group>
<source>Valtimoterveydeksi! Terveyden edist&#x000e4;misen k&#x000e4;sikirja. [For cardiovascular health! Handbook of health promotion]</source>. <publisher-name>Tampere, Ministry of Health and Social Affairs, Diabetes Association, Heart Association</publisher-name>, <year>2010</year>.</mixed-citation></ref></ref-list></back></article>